21668-34-8

Upstream product

• 21553-46-8 4-methoxy-3,5-dimethylbenzoic acid 

Downstream Products

• 1044874-33-0 C₁₉H₂₂N₂O₅ 
• 1126079-24-0 N-(3,5-dibromo-4-hydroxyphenyl)-3,5-dimethyl-4-methoxybenzamide 
• 52489-58-4 2-n-ethyl-3-(4-hydroxy-3,5-dimethylbenzoyl)benzofuran 
• 1315312-35-6 N-(2,4-dichloro-pyrimidin-5-yl)-4-methoxy-3,5-dimethyl-benzamide 
• 1315456-69-9 2-(4-methoxy-3,5-dimethyl-benzoylamino)-malonic acid diethyl ester 
• 1315456-71-3 sodium 4,6-dihydroxy-5-(4-methoxy-3,5-dimethyl-benzoylamino)-pyrimidine-2-thiolate 
• 1315456-72-4 N-(4,6-dihydroxy-2-methylsulfanyl-pyrimidin-5-yl)-4-methoxy-3,5-dimethyl-benzamide 
• 1417620-27-9 7-chloro-2-(4-methoxy-3,5-dimethylphenyl)-5-methylsulfanyloxazolo[5,4-d]pyrimidine 
• 1417620-28-0 4-(7-chloro-5-methylsulfanyloxazolo[5,4-d]pyrimidin-2-yl)-2,6-dimethylphenol 
• 1417620-32-6 tert-butyl {4-[5-(2,5-difluorophenoxy)-7-propyloxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethylphenoxy}acetate 
• 1417620-18-8 C₂₄H₂₁F₂N₃O₅ 
• 1417620-33-7 tert-butyl {2,6-dimethyl-4-[7-propyl-5-(3,3,3-trifluoropropoxy)oxazolo[5,4-d]pyrimidin-2-yl]phenoxy}acetate 
• 1417658-82-2 N-(2,6-dichloropyridin-3-yl)-4-methoxy-3,5-dimethylbenzamide 
• 1417658-84-4 5-(2-fluorophenoxy)-2-(4-methoxy-3,5-dimethylphenyl)oxazolo[5,4-b]pyridine 

Relevant academic research and scientific papers

Used for the prevention and treatment of cardiovascular diseases

The invention relates to compounds that can be used for adjusting the expression of apolipoprotein A-I (ApoA-I) and usage of the compounds in treating and preventing cardiovascular diseases and related diseases, including the disorder related to cholesterol or lipids such as atherosclerosis.

DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION

A compound represented by the general Formula (I): a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a pro-drug thereof, a deuterated radio-labeled analog thereof, and mixtures of any of the foregoing, wherein: A - K are individually selected from carbon or nitrogen; X = -O, -NR1,or -S; R1-11 are individually selected from the group consisting of-H, C1-C6 alkyl, C6-C aryl, substituted C6-C14 aryl, C1-C14-alkoxy, halogen, hydroxyl, carboxy, cyano, C1-C6-alkanoyloxy, C1-C6-alkylthio, C1-C6-alkylsulfonyl, trifluoromethyl, hydroxy, C2-C6-alkoxycarbonyl, C2-C6-alkanoylamino, -O-R12, S-R12,-SO2-Ri2, -NHSO2R12 and -NHCO2R12, wherein R12 is phenyl, naphthyl, or phenyl or naphthly substituted with one to three groups selected from C1-C6-alkyl, C6-C10 aryl,C1-C6-alkoxy and halogen, and C4-C20 hydroxyheteroaryl wherein the heteroatoms are selected from the group consisting of sulfur, nitrogen, and oxygen.

Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies

Transthyretin (TTR) amyloidogenesis inhibitors are typically composed of two aromatic rings and a linker. We have previously established optimal structures for one aromatic ring and the linker. Herein, we employ a suboptimal linker and an optimal aryl-X substructure to rank order the desirability of aryl-Z substructures-using a library of 56 N-(3,5-dibromo-4-hydroxyphenyl) benzamides. Coconsideration of amyloid inhibition potency and ex vivo plasma TTR binding selectivity data reveal that 2,6, 2,5, 2, 3,4,5, and 3,5 substituted aryls bearing small substituents generate the most potent and selective inhibitors, in descending order. These benzamides generally lack undesirable thyroid hormone receptor binding and COX-1 inhibition activity. Three high-resolution TTR ? inhibitor crystal structures (1.31-1.35 ?) provide insight into why these inhibitors are potent and selective, enabling future structure-based design of TTR kinetic stabilizers.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotei? A-I (ApoA-l), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

Substituted benzofurans and benzothiophenes

The compounds are benzoyl benzofurans and benzothiophenes having pharmacological activity, in particular, coronary vasodilator activity useful for the treatment of angina pectoris and intermediates for the preparation thereof.